• Home
  • »
  • About Alexion

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Alexion developed Soliris® (eculizumab), the world’s first approved terminal complement inhibitor, from the laboratory through commercialization. Today, Soliris is approved in more than 50 countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and in more than 40 countries for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). PNH and aHUS are two life-threatening, ultra-rare disorders caused by uncontrolled complement activation. Download Soliris prescribing information (PDF). As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders.

Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D). Strensiq is approved in the U.S., EU, Japan and Canada, and Kanuma is approved in the U.S., EU. and Japan.

Alexion's new world headquarters in New Haven, CT

Alexion's new world headquarters in New Haven, Connecticut 


As we continue to expand our operations to serve more patients in additional countries, Alexion has emerged as one of the world's leading rare disease companies. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities.

Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.

Our global headquarters and research operations are in New Haven, Conn. Alexion's approximately 3,000 employees around the world serve patients in 50 countries.

Share, Send, or Save